Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954

Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular biology 2007-04, Vol.368 (2), p.481-492
Hauptverfasser: Race, Paul R., Lovering, Andrew L., White, Scott A., Grove, Jane I., Searle, Peter F., Wrighton, Christopher W., Hyde, EvaI
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 492
container_issue 2
container_start_page 481
container_title Journal of molecular biology
container_volume 368
creator Race, Paul R.
Lovering, Andrew L.
White, Scott A.
Grove, Jane I.
Searle, Peter F.
Wrighton, Christopher W.
Hyde, EvaI
description Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme–prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this system. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and F124 affect the interactions with nicotinic acid. The structure of double mutant N71S/F124K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied.
doi_str_mv 10.1016/j.jmb.2007.02.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70338335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022283607001799</els_id><sourcerecordid>19542905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-5c0d1f9973e9b1f4edc907692781d6e26357902dc6b2632602c4426c0e61c0bb3</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYpqBD2CDvGKXULbzFCto9cCI4SE1rC2nXJm4lcSD7Qyaj-CfSatbYgerskrnXpV8GHspIBcgqjeH_DB1uQSoc5A5CPmIbQQ0bdZUqnnMNgBSZrJR1QV7FuMBAEpVNE_ZhahVCVDAhv3-5GZKDrmZLd-nsGBaghn5djDBYKLgoknOz9z3fBdxWBc4OMPRj45_cSn4QHYNmUj885LMnCLfD_6Xm2_59XQX_D1Zvut7hwYfeO8DTwPxb8HbsNzy_dLFFEwivn0v2rJ4zp70Zoz04jwv2Y-r3fftx-zm64fr7bubDFUjU1YiWNG3ba2o7URfkMUW6qqVdSNsRbJSZd2CtFh161tWILEoZIVAlUDoOnXJXp961wN_LhSTnlxEGkczk1-irkGpRqnyv-DxaNnCERQnEIOPMVCv74KbTHjQAvRRlj7oVZY-ytIg9Sprzbw6ly_dRPZv4mxnBd6eAFr_4t5R0BEdzUjWBcKkrXf_qP8DvQ2lnA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19542905</pqid></control><display><type>article</type><title>Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Race, Paul R. ; Lovering, Andrew L. ; White, Scott A. ; Grove, Jane I. ; Searle, Peter F. ; Wrighton, Christopher W. ; Hyde, EvaI</creator><creatorcontrib>Race, Paul R. ; Lovering, Andrew L. ; White, Scott A. ; Grove, Jane I. ; Searle, Peter F. ; Wrighton, Christopher W. ; Hyde, EvaI</creatorcontrib><description>Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme–prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this system. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and F124 affect the interactions with nicotinic acid. The structure of double mutant N71S/F124K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1016/j.jmb.2007.02.012</identifier><identifier>PMID: 17350040</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aziridines - chemistry ; Aziridines - metabolism ; Binding Sites ; Catalysis ; CB1954 ; Chromatography, High Pressure Liquid ; Crystallography, X-Ray ; Escherichia coli ; Escherichia coli - enzymology ; gene therapy ; Hydroxylamine ; Kinetics ; Models, Molecular ; Mutant Proteins - chemistry ; Mutation - genetics ; Niacin - metabolism ; Nitrofurazone - metabolism ; nitroreductase ; Nitroreductases - chemistry ; Oxidation-Reduction ; Prodrugs - metabolism ; protein engineering ; Protein Structure, Secondary ; Substrate Specificity ; X-ray structure</subject><ispartof>Journal of molecular biology, 2007-04, Vol.368 (2), p.481-492</ispartof><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-5c0d1f9973e9b1f4edc907692781d6e26357902dc6b2632602c4426c0e61c0bb3</citedby><cites>FETCH-LOGICAL-c382t-5c0d1f9973e9b1f4edc907692781d6e26357902dc6b2632602c4426c0e61c0bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jmb.2007.02.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17350040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Race, Paul R.</creatorcontrib><creatorcontrib>Lovering, Andrew L.</creatorcontrib><creatorcontrib>White, Scott A.</creatorcontrib><creatorcontrib>Grove, Jane I.</creatorcontrib><creatorcontrib>Searle, Peter F.</creatorcontrib><creatorcontrib>Wrighton, Christopher W.</creatorcontrib><creatorcontrib>Hyde, EvaI</creatorcontrib><title>Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme–prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this system. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and F124 affect the interactions with nicotinic acid. The structure of double mutant N71S/F124K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied.</description><subject>Aziridines - chemistry</subject><subject>Aziridines - metabolism</subject><subject>Binding Sites</subject><subject>Catalysis</subject><subject>CB1954</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Crystallography, X-Ray</subject><subject>Escherichia coli</subject><subject>Escherichia coli - enzymology</subject><subject>gene therapy</subject><subject>Hydroxylamine</subject><subject>Kinetics</subject><subject>Models, Molecular</subject><subject>Mutant Proteins - chemistry</subject><subject>Mutation - genetics</subject><subject>Niacin - metabolism</subject><subject>Nitrofurazone - metabolism</subject><subject>nitroreductase</subject><subject>Nitroreductases - chemistry</subject><subject>Oxidation-Reduction</subject><subject>Prodrugs - metabolism</subject><subject>protein engineering</subject><subject>Protein Structure, Secondary</subject><subject>Substrate Specificity</subject><subject>X-ray structure</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYpqBD2CDvGKXULbzFCto9cCI4SE1rC2nXJm4lcSD7Qyaj-CfSatbYgerskrnXpV8GHspIBcgqjeH_DB1uQSoc5A5CPmIbQQ0bdZUqnnMNgBSZrJR1QV7FuMBAEpVNE_ZhahVCVDAhv3-5GZKDrmZLd-nsGBaghn5djDBYKLgoknOz9z3fBdxWBc4OMPRj45_cSn4QHYNmUj885LMnCLfD_6Xm2_59XQX_D1Zvut7hwYfeO8DTwPxb8HbsNzy_dLFFEwivn0v2rJ4zp70Zoz04jwv2Y-r3fftx-zm64fr7bubDFUjU1YiWNG3ba2o7URfkMUW6qqVdSNsRbJSZd2CtFh161tWILEoZIVAlUDoOnXJXp961wN_LhSTnlxEGkczk1-irkGpRqnyv-DxaNnCERQnEIOPMVCv74KbTHjQAvRRlj7oVZY-ytIg9Sprzbw6ly_dRPZv4mxnBd6eAFr_4t5R0BEdzUjWBcKkrXf_qP8DvQ2lnA</recordid><startdate>20070427</startdate><enddate>20070427</enddate><creator>Race, Paul R.</creator><creator>Lovering, Andrew L.</creator><creator>White, Scott A.</creator><creator>Grove, Jane I.</creator><creator>Searle, Peter F.</creator><creator>Wrighton, Christopher W.</creator><creator>Hyde, EvaI</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20070427</creationdate><title>Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954</title><author>Race, Paul R. ; Lovering, Andrew L. ; White, Scott A. ; Grove, Jane I. ; Searle, Peter F. ; Wrighton, Christopher W. ; Hyde, EvaI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-5c0d1f9973e9b1f4edc907692781d6e26357902dc6b2632602c4426c0e61c0bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aziridines - chemistry</topic><topic>Aziridines - metabolism</topic><topic>Binding Sites</topic><topic>Catalysis</topic><topic>CB1954</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Crystallography, X-Ray</topic><topic>Escherichia coli</topic><topic>Escherichia coli - enzymology</topic><topic>gene therapy</topic><topic>Hydroxylamine</topic><topic>Kinetics</topic><topic>Models, Molecular</topic><topic>Mutant Proteins - chemistry</topic><topic>Mutation - genetics</topic><topic>Niacin - metabolism</topic><topic>Nitrofurazone - metabolism</topic><topic>nitroreductase</topic><topic>Nitroreductases - chemistry</topic><topic>Oxidation-Reduction</topic><topic>Prodrugs - metabolism</topic><topic>protein engineering</topic><topic>Protein Structure, Secondary</topic><topic>Substrate Specificity</topic><topic>X-ray structure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Race, Paul R.</creatorcontrib><creatorcontrib>Lovering, Andrew L.</creatorcontrib><creatorcontrib>White, Scott A.</creatorcontrib><creatorcontrib>Grove, Jane I.</creatorcontrib><creatorcontrib>Searle, Peter F.</creatorcontrib><creatorcontrib>Wrighton, Christopher W.</creatorcontrib><creatorcontrib>Hyde, EvaI</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Race, Paul R.</au><au>Lovering, Andrew L.</au><au>White, Scott A.</au><au>Grove, Jane I.</au><au>Searle, Peter F.</au><au>Wrighton, Christopher W.</au><au>Hyde, EvaI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>2007-04-27</date><risdate>2007</risdate><volume>368</volume><issue>2</issue><spage>481</spage><epage>492</epage><pages>481-492</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><abstract>Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme–prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this system. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and F124 affect the interactions with nicotinic acid. The structure of double mutant N71S/F124K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>17350040</pmid><doi>10.1016/j.jmb.2007.02.012</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2836
ispartof Journal of molecular biology, 2007-04, Vol.368 (2), p.481-492
issn 0022-2836
1089-8638
language eng
recordid cdi_proquest_miscellaneous_70338335
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Aziridines - chemistry
Aziridines - metabolism
Binding Sites
Catalysis
CB1954
Chromatography, High Pressure Liquid
Crystallography, X-Ray
Escherichia coli
Escherichia coli - enzymology
gene therapy
Hydroxylamine
Kinetics
Models, Molecular
Mutant Proteins - chemistry
Mutation - genetics
Niacin - metabolism
Nitrofurazone - metabolism
nitroreductase
Nitroreductases - chemistry
Oxidation-Reduction
Prodrugs - metabolism
protein engineering
Protein Structure, Secondary
Substrate Specificity
X-ray structure
title Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A46%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Kinetic%20and%20Structural%20Characterisation%20of%20Escherichia%20coli%20Nitroreductase%20Mutants%20Showing%20Improved%20Efficacy%20for%20the%20Prodrug%20Substrate%20CB1954&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=Race,%20Paul%20R.&rft.date=2007-04-27&rft.volume=368&rft.issue=2&rft.spage=481&rft.epage=492&rft.pages=481-492&rft.issn=0022-2836&rft.eissn=1089-8638&rft_id=info:doi/10.1016/j.jmb.2007.02.012&rft_dat=%3Cproquest_cross%3E19542905%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19542905&rft_id=info:pmid/17350040&rft_els_id=S0022283607001799&rfr_iscdi=true